Drug Profile

INCA 035784

Alternative Names: INCA-035784

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Myeloproliferative disorders

Most Recent Events

12 Jun 2025 Pharmacodynamics data from a preclinical trial in Myeloproliferative disorders presented at the European Hematology Association (EHA-2025)
06 Jun 2025 Preclinical trials in Myeloproliferative disorders in USA (unspecified route) prior to June 2025.
06 Jun 2025 Incyte Corporation plans a phase I trial for Myeloproliferative Neoplasms (Second-line therapy or greater) in July 2025 (NCT07008118)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com